At the end of last year, I proclaimed Omontys -- an erythropoiesis-stimulating agent, or ESA, that aids in the formation of red blood cells -- as one of my 10 drugs approved by the Food and Drug Administration in 2012 to be thankful for. The drug, developed by Affymax and Takeda Pharmaceuticals , was designed to be a once-a-month injectable treatment for patients on dialysis with chronic kidney disease. Today, it's the straw that broke Affymax shareholders' back.
On Saturday, Affymax and Takeda, in cooperation with the FDA, announced the voluntary recall of all lots of injectable Omontys. According to the release, more than 25,000 patients have received the anemia drug since it launched, with 0.2% of them responding with a hypersensitivity reaction that -- in a third of those patients -- led to anaphylaxis. Fatal reactions were reported in 0.02% of all cases where Omontys was administered.
Houston, we have a problem.
For Takeda, the blow isn't as severe, as it's a large pharmaceutical company with dozens of partnerships. For Affymax, this is a completely different story.
In its third-quarter results, released in November, Affymax noted Omontys sales of just $15 million -- it wasn't exactly selling like hotcakes to begin with -- and noted at the time that the company wouldn't be receiving any further milestone or profit equalization payments from Takeda for 2012. Moving forward, it's not going to be receiving anything as Omontys is Affymax's only approved drug. Keep in mind that operating expenses including stock-based compensation were guided to a whopping $130 million to $135 million last quarter, and it boasts just $100 million in cash and investments.
OK... breathe... Affymax had to have thought this through and clearly has other compounds in its pipeline, right? That'd be wishful thinking because it only has two other compounds in clinical trials: a late-stage conversion study on -- you guessed it -- Omontys for use as a once-a-week ESA as opposed to three times a week, and a mid-stage study outside of the U.S. utilizing Omontys to treat dialysis and non-dialysis related anemia for patients with pure red cell aplasia.
(Bangs head on table)
It gets even worse. Let's assume for a moment that Affymax and Takeda are able to work out these not-so-minor kinks with Omontys to the FDA's satisfaction -- it'll still be giving Amgen even more time to further its market share lead. Amgen, which makes Epogen -- the leading anemia treatment for the past two decades -- fortified its market-leading spot a while ago by signing multi-year dialysis center agreements with DaVita and Fresenius Medical Care . They're arguably the two biggest names in dialysis, as my Foolish colleague Brandy Betz noted last month. While this doesn't negate Affymax from dealing with DaVita and Fresenius, it makes orchestrating an agreement far less likely.
This is the danger of investing in a one-trick pony. There are plenty of one-drug biotechs in existence that have fared quite well -- including Alexion Pharmaceuticals with Soliris - but Affymax is quick to remind us of the dangers of putting all your eggs in just one basket. Only time will tell if Omontys can be saved, but, for the time being, Affymax shares should be counted as damaged goods.
While you can certainly hope to make huge gains in biotechs like Affymax, the best investing approach is to choose great companies and stick with them for the long term. The Motley Fool's free report "3 Stocks That Will Help You Retire Rich" names stocks that could help you build long-term wealth and retire well, along with some winning wealth-building strategies that every investor should be aware of. Click here now to keep reading.
The article Behold the Dangers of a One-Trick Pony originally appeared on Fool.com.Fool contributor Sean Williams has no material interest in any companies mentioned in this article. You can follow him on CAPS under the screen name TMFUltraLong, track every pick he makes under the screen name TrackUltraLong, and check him out on Twitter, where he goes by the handle @TMFUltraLong. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.